| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 01/17/2002 | US20020006443 Drug in a solubility-improved form with a concentration-enhancing polymer such as hydroxypropyl methyl cellulose acetate succinate; combination improves bioavailability relative to a control of just solubility improved form |
| 01/17/2002 | US20020006442 Injectable aqueous dispersions of propofol |
| 01/17/2002 | US20020006441 Pharmaceutical composition containing diphosphonic acid or salt thereof |
| 01/17/2002 | US20020006440 For psychotropic, a gastrointestinal therapeutic or a migraine therapeutic; melts quickly in mouth of patient without requiring chewing; mouthfeel; binder, salivating agent, diluent/bulking agent, drug |
| 01/17/2002 | US20020006439 For oral administration, comprising a semipermeable membrane surrounding a therapeutic composition comprising a dose of drug; dosage form imbibes fluid through the membrane in response to concentration gradient; sustained release |
| 01/17/2002 | US20020006438 Solid once-a-day oral dosage form with a sustained release carrier that provides rapid rise in plasma concentration in early peak concentration followed by second broader peak with plateau plasma concentrations |
| 01/17/2002 | US20020006437 Biocompatible implant comprising an osteogenic and/or regenerative material covered by a protective capsule of tissue or other biocompatible substance to prevent undesirable migration of the material from site of implant |
| 01/17/2002 | US20020006436 Use of a liquid crystalline phase for determining the distribution of a chemical substance between a hydrophobic and a hydrophilic environment |
| 01/17/2002 | US20020006433 Chewable tablet comprising amoxycillin trihydrate in which the chewable base comprises mannitol which is at least twenty-five percent by weight of the tablet; treating bacterial infection in a pediatric patient |
| 01/17/2002 | US20020006432 Bifidobacterium in the treatment of inflammatory disease |
| 01/17/2002 | US20020006430 Angiotensin converting enzyme (ACE) inhibitor; controlled release diltiazem in the core in combination with a rapid release ACE inhibitor, or diuretic, in an external coat; pharmacokinetics; easier to swallow; treating hypertension |
| 01/17/2002 | US20020006427 Process for producing ceramics |
| 01/17/2002 | US20020006418 Composition to enhance permeation of topical skin agents |
| 01/17/2002 | US20020006417 Heating the fill mass, cooling the fill mass, and encapsulating the fill mass into the capsule immediately after cooling; nutrients or drugs such as saquinavir |
| 01/17/2002 | US20020006416 Use of an extract of gaboon resin |
| 01/17/2002 | US20020006410 Method for treating inflammatory diseases using heat shock proteins |
| 01/17/2002 | US20020006409 Composition and method of cancer antigen immunotherapy |
| 01/17/2002 | US20020006388 Flexible, conforming strip |
| 01/17/2002 | US20020006384 Using fluorohydrocarbons as propellant |
| 01/17/2002 | US20020006383 Promoter of biosynthesis of skin cells |
| 01/17/2002 | US20020005028 Methods of producing a terminally sterilized topical patch preparation |
| 01/17/2002 | DE10032132A1 Dermales Therapeutisches System enthaltend nichtsteroidale Antiphlogistika mit selektiver COX-2-Hemmung A dermal therapeutic system containing NSAIDs with selective COX-2 inhibition |
| 01/17/2002 | DE10031741A1 Externally applied oxygen carrier preparation for treating oxygen deficiency states of the skin, comprises active agent, specifically hemoglobin or its mixture with myoglobin, incorporated in a gel carrier |
| 01/17/2002 | DE10031132A1 Verfahren zur Herstellung aktivstoffhaltiger Kapseln mit ultradünner Wandschicht Process for the preparation aktivstoffhaltiger capsules with an ultra-thin layer |
| 01/17/2002 | CA2427066A1 Method for the recovery and application of human defensins as biologically active proteins for the treatment of infections and other diseases |
| 01/17/2002 | CA2416050A1 Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections |
| 01/17/2002 | CA2415778A1 Methods of therapy with thrombin derived peptides |
| 01/17/2002 | CA2415695A1 Compositions and methods for treatment of anal fissure |
| 01/17/2002 | CA2415658A1 Transdermal therapeutic system for highly dispersed silicon dioxide |
| 01/17/2002 | CA2415630A1 Tablet obtained by direct compression comprising 4-amino-1-hydroxybutylidene-1, 1-bisphosphonic acid as active ingredient |
| 01/17/2002 | CA2415498A1 Macrolide formulations for inhalation and methods of treatment of endobronchial infections |
| 01/17/2002 | CA2415483A1 Antisense compositions targeted to .beta.1 adrenoceptor-specific mrna and methods of use |
| 01/17/2002 | CA2415237A1 Non swellable suppository comprising at least one biocompatible, non-biodegradable polymer and a controlled release formulation |
| 01/17/2002 | CA2415124A1 Use of a liquid medicament in surgical high pressure liquid jet devices |
| 01/17/2002 | CA2415092A1 Novel aerosol formulation containing a polar fluorinated molecule |
| 01/17/2002 | CA2415082A1 Method for formulating healthcare products with enhanced stability |
| 01/17/2002 | CA2415081A1 Drug delivery system for poorly water soluble drugs |
| 01/17/2002 | CA2415080A1 Improved thyroid hormone formulations |
| 01/17/2002 | CA2415058A1 Pharmaceutical compositions of estrogenic agents |
| 01/17/2002 | CA2414926A1 Microspheres and adjuvants for dna vaccine delivery |
| 01/17/2002 | CA2413549A1 Substrates for powder deposition containing conductive domains |
| 01/16/2002 | EP1172373A2 Method for preparing zinc-oligopeptide easily absorbable by the human body |
| 01/16/2002 | EP1172114A2 Stable concentrated insulin preparations for pulmonary delivery |
| 01/16/2002 | EP1172104A1 Seam soft capsule preparations containing dihydrobenzofuran derivative |
| 01/16/2002 | EP1172100A1 Oral solid pharmaceutical formulations with ph-dependent multiphasic release |
| 01/16/2002 | EP1172099A1 Method for transferring one or more active ingredients between different phase carriers |
| 01/16/2002 | EP1172098A1 Pharmaceutical compositions comprising ketotifen |
| 01/16/2002 | EP1172097A1 Process for producing medicinal composition of basic hydrophobic medicinal compound |
| 01/16/2002 | EP1172077A1 Nanoemulsion containing nonionic polymers |
| 01/16/2002 | EP1171612A2 Telomerase-specific cancer vaccine |
| 01/16/2002 | EP1171573A1 Arpe-19 as a platform cell line for encapsulated cell-based delivery |
| 01/16/2002 | EP1171490A1 Fluorinated copolymers for coating biomedical devices and a process for their manufacture |
| 01/16/2002 | EP1171471A1 Enhanced gel strength methylcellulose |
| 01/16/2002 | EP1171161A1 Treatment of adult rheumatoid arthritis by oral administration of pooled human immunoglobulin and an antacid |
| 01/16/2002 | EP1171159A2 Combination vaccine against streptococcus pneumoniae and respiratory syncytial virus (rsv) |
| 01/16/2002 | EP1171153A2 Novel medical use of alpha-1-acidic glycoprotein (aag) or orosomucoid |
| 01/16/2002 | EP1171150A2 Pseudomycin antifungal compositions and methods for their use |
| 01/16/2002 | EP1171136A2 Immunomodulating composition for use especially in the treatment of inflammations, infections and surgical adhesions |
| 01/16/2002 | EP1171134A1 Controlled release of sildenafil delivered by sublingual or buccal administration |
| 01/16/2002 | EP1171132A1 Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol |
| 01/16/2002 | EP1171124A2 Anthelmintic compositions |
| 01/16/2002 | EP1171121A2 Pharmaceutical compositions comprising dipeptidylpeptidase iv inhibitors for the promotion of growth |
| 01/16/2002 | EP1171118A2 Methods and compositions for enhancing delivery of therapeutic agents to tissues |
| 01/16/2002 | EP1171115A1 Methods of delivery of cetyl myristoleate |
| 01/16/2002 | EP1171111A2 Granulate with high content of l-carnitine or an alkanoyl l-carnitine |
| 01/16/2002 | EP1171107A1 Pharmaceutical composition effective against pathological conditions caused by bacteria, viruses, fungi, yeasts and protozoa |
| 01/16/2002 | EP1171105A1 Transdermal therapeutic system with a highly effective neuroleptic agent |
| 01/16/2002 | EP1171104A2 Transdermal therapeutic system with neutralized acrylic adhesive patch |
| 01/16/2002 | EP1171103A2 Inactivated microorganisms comprising substances having pharmacological activity |
| 01/16/2002 | EP1171102A1 Anhydrous tablet of ranitidine hydrochloride with double-layer coating and its composition |
| 01/16/2002 | EP1171101A1 Method for producing a water-insoluble amorphous or partially amorphous controlled release matrix |
| 01/16/2002 | EP1171100A1 Solubilized pharmaceutical composition for parenteral administration |
| 01/16/2002 | EP1171099A1 Composition containing opioid antagonists and spray dispenser |
| 01/16/2002 | EP1171098A1 A method for improving the half-life of soluble viral-specific ligands on mucosal membranes |
| 01/16/2002 | EP1171097A1 A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate |
| 01/16/2002 | EP1171091A1 Pharmaceutical or cosmetic compositions for the local, intradermal application of hormones |
| 01/16/2002 | EP1171080A2 Mousse forming hair treatment composition |
| 01/16/2002 | EP1171057A1 Cell-culture and polymer constructs |
| 01/16/2002 | EP1159049A4 Responsive gels and methods of use thereof |
| 01/16/2002 | EP1093374B1 Hypo-osmotic saline solutions, method for preparing same and medicines based on said solutions |
| 01/16/2002 | EP1024793B1 Osmotic medicament releasing system |
| 01/16/2002 | EP0969811B1 Mixtures of alkylphosphoric acid esters and their use as cosmetic and pharmaceutical emulsifiers |
| 01/16/2002 | EP0964846B1 Process for preparing aromatic polyamine mixtures |
| 01/16/2002 | EP0960131B1 Manufacture of cross-linked amylose useful as an excipient for control release of active compounds |
| 01/16/2002 | EP0952839B1 Green ointment |
| 01/16/2002 | EP0914097B1 Composition and dosage form comprising opioid antagonist |
| 01/16/2002 | EP0859626B1 Pharmaceutical preparation containing cyclosporin(s) for oral administration and process for producing the said preparation |
| 01/16/2002 | EP0830132B1 Pharmaceutical composition containing tiagabine hydrochloride and the process for its preparation |
| 01/16/2002 | EP0817645B1 Use of gonadotropin in the treatment of benign prostatic hypertrophy |
| 01/16/2002 | EP0772434B1 Method of preparing natural-oil-containing emulsions and microcapsules and its uses |
| 01/16/2002 | CN1331703A Substance for reduction of cholesterol as well as lipids content |
| 01/16/2002 | CN1331698A Brain cell or nerve cell-protective agents comprising ginsenoside Rb1 |
| 01/16/2002 | CN1331606A Oil-in-water emulsion exhibiting protective action against damages to human organs resulting from peroxidation and prodn. and use thereof |
| 01/16/2002 | CN1331605A Sustained-release particles |
| 01/16/2002 | CN1331604A Compsn. consisting of influenza virus surface proteins and dispensing device |
| 01/16/2002 | CN1331596A Controlled release galantamine composition |
| 01/16/2002 | CN1331592A Liposomic niflumic acid-new transdermal anti-inflammatory medicine |
| 01/16/2002 | CN1331590A Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating disease associated with increase of AT-1 or AT-2 receptors |
| 01/16/2002 | CN1331587A Spray-type consmetic compsn. and matrix used in said compsn. for dermal administration |
| 01/16/2002 | CN1331586A Transparent transdermal nicotine delivery devices |